New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer. Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 clinical trial published in The New England Journal of Medicine.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 clinical trial published in The New England Journal of Medicine.
- Ponto de atenção: treatment.
- Ponto de atenção: approach.
- Ponto de atenção: improves.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
